Mitochondrial Genetic Polymorphisms and Pancreatic Cancer Risk

  1. Liang Wang1,
  2. William R. Bamlet2,
  3. Mariza de Andrade2,
  4. Lisa A. Boardman3,
  5. Julie M. Cunningham1,
  6. Stephen N. Thibodeau1 and
  7. Gloria M. Petersen2
  1. Departments of 1Laboratory Medicine and Pathology, 2Health Sciences Research, and 3Gastroenterology, Mayo Clinic College of Medicine, Rochester, Minnesota
  1. Requests for reprints:
    Liang Wang, Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, 200 First Street Southwest, Stabile 241, Rochester, MN 55905. Phone: 507-284-9136; Fax: 507-266-5193. E-mail: wang.liang{at}mayo.edu

Abstract

The role of genes that influence the risk of developing pancreatic cancer (PC) has not been well studied. The mitochondrion, conventionally thought to be an organelle specific to energy metabolism, is in fact multifunctional and has been implicated in many diseases, including cancer. To evaluate whether single nucleotide polymorphisms in mitochondrial DNA (mtSNP) are associated with increased risk of PC, we screened Caucasian cases diagnosed or seen at the Mayo Clinic with primary pancreatic adenocarcinoma (n = 955), and healthy clinic-based Caucasian controls (n = 1,102). A total of 24 mtSNPs, including 10 of the most common tagSNPs, 7 non-tagSNPs in the coding region, and 7 common SNPs in the regulatory region were genotyped. For analysis, these samples were grouped into two phases, the “testing” set (474 cases and 615 controls), and the “validation” set (481 cases and 487 controls). In the testing set, one mtSNP (SNP11719) suggested an association in single SNP analysis, with an odds ratio of 1.34 (95% confidence intervals, 1.05-1.72; P = 0.020), but did not remain statistically significant after correction for multiple testing. In the validation set, none of the 24 variants indicated any association with PC. For haplogroup analysis, 10 core SNPs that form common haplogroups in Caucasians (1719, 4580, 7028, 8251, 9055, 10398, 12308, 13368, 13708, and 16391) were evaluated. No significant associations with PC were identified either by analyzing the two sets separately or combined (combined global P = 0.17). Overall, these results do not support a significant involvement of mitochondrial DNA variation in the risk of developing PC. Investigation of other mitochondrial genetic variations (i.e., nuclear-encoded mitochondrial proteins) would be necessary to elucidate any role of mitochondrial DNA variation in PC. (Cancer Epidemiol Biomarkers Prev 2007;16(7):1455–9)

Footnotes

  • 4 http://www.mitomap.org

  • Grant support: National Cancer Institute P50 CA102701 (Mayo Clinic Specialized Programs of Research Excellence in Pancreatic Cancer).

  • The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted May 10, 2007.
    • Received February 7, 2007.
    • Revision received April 28, 2007.
« Previous | Next Article »Table of Contents